Live Analysis:
Smith & Nephew plc (SNN) saw a price drop of 85 cents, representing a 2.65% decrease from the previous close, currently trading at $31.24. Trading volume spiked significantly, reaching $577,607, 64.39% higher than the average.
Earnings Overview:
SNN's latest quarterly earnings report, released on March 2nd, revealed an earnings per share of $1.18, slightly surpassing the consensus estimate of $1.16.
Dividends:
The company offers a forward dividend yield of 5.98%, with a dividend per share of 30 cents in the most recent quarter. Year-over-year dividend per share increased by 1.6 cents, standing at $1.23 trailing twelve months.
Cash Flow:
Operating cash flow for the period was $888.43 million, with notable activities including acquisitions netting $25 million and debt repayment of $100.33 million. Common stock repurchased totaled $503.17 million, resulting in a net cash decrease of $118.41 million.
Income Statement:
SNN reported a net income of $330.82 million, with an earnings per share of 78 cents. Revenue stood at $3.19 billion, generating a gross profit of $2 billion.
Ratios:
Key ratios include a net profit margin of 10.36%, return on equity of 6.47%, and a price-to-earnings ratio of 10.55.
Balance Sheet:
The balance sheet reflects total assets of $10.46 billion and total liabilities of $5.17 billion, with net debt at $2.77 billion.
This real-time financial report provides insights into SNN's performance and financial health as the market session draws to a close.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.